30 papers
Endocrinology explores the complex network of hormones that regulate nearly every function in the human body, from metabolism and growth to mood and reproduction. When this delicate chemical signaling system falters, it can lead to a wide range of conditions, including diabetes, thyroid disorders, and fertility issues. Understanding these mechanisms is vital for developing treatments that restore balance and improve quality of life.
At Gist.Science, we make the latest research from medRxiv accessible to everyone. We process every new preprint in this category as it becomes available, transforming dense medical findings into clear, plain-language overviews alongside detailed technical summaries. This approach ensures that both curious readers and specialists can stay informed without getting lost in jargon.
Below are the latest endocrinology preprints we have processed, offering fresh insights into how our internal chemistry shapes health and disease.
This retrospective study of over 103 million women using TriNetX data reveals that pain affects approximately 20.67% of women with PCOS, with significant racial disparities in prevalence and associated health risks, while also demonstrating that PCOS-related medications effectively reduce pain diagnoses.
This study reveals that the HbE thalassaemia trait, which is prevalent but often undiagnosed among British South Asians, artificially elevates HbA1c levels without increasing blood glucose, leading to the overdiagnosis and overtreatment of type 2 diabetes and a distorted assessment of complication risks.
This preregistered living systematic review and meta-analysis provides evidence that exogenous oxytocin reduces appetite and caloric intake in specific patient groups, such as those with obesity or type II diabetes, but finds no statistically significant effects in healthy individuals, suggesting the need for further research to draw definitive conclusions.
This living systematic review and meta-analysis of 31 placebo-controlled trials involving over 40,000 patients found no significant association between semaglutide or tirzepatide treatment and an increased risk of acute pancreatitis compared to placebo.
This multicenter cross-sectional study in northern Nigeria reveals that dyslipidemia affects nearly 60% of diabetes patients, is independently associated with female gender and proteinuria, and remains poorly managed with only 17.1% of patients achieving cardiovascular risk targets due to limited treatment options and low guideline adherence.
This large cross-sectional study of 1,300 women with polycystic ovary syndrome (PCOS) found that thyroid autoimmunity is not associated with a more severe cardiometabolic or androgenic phenotype, suggesting that anti-TPO positivity alone does not identify a metabolically high-risk PCOS subgroup.
This study utilizing UK Biobank data reveals that while the Edmonton Obesity Staging System and the Lancet Commission Diagnostic Model show high concordance for established disease, they differ significantly in early-stage classification due to distinct operational definitions of organ dysfunction, suggesting that integrating both frameworks could enhance obesity risk stratification and intervention targeting.
This study applies a causal mediation framework enhanced by a Causally-constrained Linear Autoencoder to continuous glucose monitoring data from Type 1 Diabetes patients, revealing significant heterogeneity in how carbohydrate intake affects glucose levels through direct versus insulin-mediated pathways, particularly highlighting systematic under-compensation at dinner that is masked by population-average analyses.
This cross-sectional NHANES study reveals that kidney stones are independently associated with reduced femoral neck bone mineral density, a relationship partially mediated by an altered calcium-to-phosphorus ratio, particularly among younger individuals and those without chronic kidney disease.
This study projects that following the 2026 patent expiry, generic semaglutide could be produced for as little as 140 annually and made available in 160 countries covering the majority of the global obesity and type 2 diabetes burden, though equitable access will depend on addressing device costs and secondary patents through coordinated policy action.